Priority 18 from the Rare Musculoskeletal Diseases in Adulthood PSP

UNCERTAINTY: Which treatments are safer and more effective for people with OI (osteogenesis imperfecta), treatments that promote bone-building (anabolic treatments) or treatments that reduce bone loss (antiresorptive treatments)? Does combining treatments make a difference? (JLA PSP Priority 18)
Overall ranking 18
JLA question ID 0076/18
Explanatory note Not available for this PSP

Health Research Classification System category Musculoskeletal
Extra information provided by this PSP
Original uncertainty examples OI: Are anabolic treatments such as teriparatide or romosozumab of any benefit? ~ Are bisphosphonates harmful or helpful in this disease? ~ Which bisphosphonate is the best for OI? ~ For OI:Is anabolic therapy better than anti-resorptive?
Submitted by Individual survey submissions categorised by Health or Social Care Professionals, Organisations representing people with rare musculoskeletal diseases, people with rare musculoskeletal diseases, relatives/carers/friends, Other.  For full details of the type of submitter for each individual question, please see the spreadsheet of data held on the JLA website.
PSP information
PSP unique ID 0076
PSP name Rare Musculoskeletal Diseases in Adulthood
Total number of uncertainties identified by this PSP. 39  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 18 June 2018